GT BIOPHARMA, INC. Interest Expense
GT BIOPHARMA, INC. (GTBP) reported Interest Expense of $213.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-15
- GT BIOPHARMA, INC. interest expense for the quarter ending 2023-12-31 was $0.00.
- GT BIOPHARMA, INC. interest expense for the quarter ending 2023-09-30 was $0.00.
- GT BIOPHARMA, INC. interest expense for the quarter ending 2023-06-30 was $1.00K.
- GT BIOPHARMA, INC. interest expense for the quarter ending 2023-03-31 was $212.00K.
- GT BIOPHARMA, INC. interest expense for fiscal 2023 was $213.00K, a 2562.50% increase from fiscal 2022.
- GT BIOPHARMA, INC. interest expense for fiscal 2022 was $8.00K, a 98.89% decline from fiscal 2021.
- GT BIOPHARMA, INC. interest expense for fiscal 2021 was $718.00K.
- GT BIOPHARMA, INC. interest expense for fiscal 2020 was -$3.00M.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $0.00 derived: sum of 2 quarters · filed 2024-03-26 | $1.00K derived: sum of 3 quarters · filed 2024-03-26 | $213.00K 10-K · filed 2024-03-26 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $1.00K derived: sum of 2 quarters · filed 2023-11-01 | $213.00K 10-Q · filed 2023-11-01 | |||||
| 2023-06-30 | $1.00K 10-Q · filed 2023-08-07 | $213.00K 10-Q · filed 2023-08-07 | ||||||
| 2023-03-31 | $212.00K 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | $8.00K 10-K · filed 2024-03-26 | |||||||
| 2022-06-30 | $700.00K 10-Q · filed 2022-08-15 | |||||||
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $22.00K derived: sum of 2 quarters · filed 2023-03-30 | $22.00K derived: sum of 3 quarters · filed 2023-03-30 | $718.00K 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-12-29 | $696.00K 10-Q · filed 2021-11-10 | -$8.53M derived: sum of 4 quarters · filed 2021-12-29 | ||||
| 2021-06-30 | $0.00 10-Q/A · filed 2021-12-29 | $696.00K 10-Q/A · filed 2021-12-29 | -$8.53M derived: sum of 3 quarters · filed 2021-12-29 | -$7.60M derived: sum of 4 quarters · filed 2021-12-29 | ||||
| 2021-03-31 | $696.00K 10-Q · filed 2021-05-17 | -$8.53M derived: sum of 2 quarters · filed 2021-05-17 | -$7.60M derived: sum of 3 quarters · filed 2021-11-10 | -$2.94M derived: sum of 4 quarters · filed 2021-12-29 | ||||
| 2020-12-31 | -$9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | -$8.30M derived: sum of 2 quarters · filed 2021-11-10 | -$3.64M derived: sum of 3 quarters · filed 2021-12-29 | -$3.00M 10-K · filed 2021-04-16 | ||||
| 2020-09-30 | $931.00K 10-Q · filed 2021-11-10 | $5.59M derived: sum of 2 quarters · filed 2021-12-29 | $6.23M 10-Q · filed 2021-11-10 | $2.61M derived: sum of 4 quarters · filed 2021-12-29 | ||||
| 2020-06-30 | $4.66M 10-Q/A · filed 2021-12-29 | $5.30M 10-Q/A · filed 2021-12-29 | $1.68M derived: sum of 3 quarters · filed 2021-12-29 | $2.23M derived: sum of 4 quarters · filed 2021-12-29 | ||||
| 2020-03-31 | $638.00K 10-Q · filed 2021-05-17 | -$2.98M derived: sum of 2 quarters · filed 2021-05-17 | -$2.42M derived: sum of 3 quarters · filed 2021-05-17 | -$1.94M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | -$3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | -$3.06M derived: sum of 2 quarters · filed 2021-04-16 | -$2.58M derived: sum of 3 quarters · filed 2021-04-16 | -$2.13M 10-K · filed 2021-04-16 | $2.13M 10-K · filed 2020-03-27 | |||
| 2019-09-30 | $560.00K 10-Q · filed 2020-11-13 | $1.04M derived: sum of 2 quarters · filed 2020-11-13 | $1.49M 10-Q · filed 2020-11-13 | $2.63M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | $479.00K 10-Q/A · filed 2020-08-18 | $933.00K 10-Q/A · filed 2020-08-18 | $2.07M derived: sum of 3 quarters · filed 2020-08-18 | $3.19M derived: sum of 4 quarters · filed 2020-08-18 | ||||
| 2019-03-31 | $454.00K 10-Q · filed 2019-05-15 | $1.59M derived: sum of 2 quarters · filed 2020-03-27 | $2.72M derived: sum of 3 quarters · filed 2020-03-27 | $6.64M derived: sum of 4 quarters · filed 2020-03-27 | ||||
| 2018-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $2.26M derived: sum of 2 quarters · filed 2020-03-27 | $6.19M derived: sum of 3 quarters · filed 2020-03-27 | $9.12M 10-K · filed 2020-03-27 | ||||
| 2018-09-30 | $1.12M 10-Q · filed 2019-11-14 | $5.05M derived: sum of 2 quarters · filed 2019-11-14 | $7.98M 10-Q · filed 2019-11-14 | $8.11M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $3.92M 10-Q · filed 2019-08-14 | $6.86M 10-Q · filed 2019-08-14 | $6.99M derived: sum of 3 quarters · filed 2019-08-14 | $10.76M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | $2.93M 10-Q · filed 2019-05-15 | $3.07M derived: sum of 2 quarters · filed 2019-05-15 | $6.83M derived: sum of 3 quarters · filed 2019-05-15 | $8.01M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $3.90M derived: sum of 2 quarters · filed 2019-03-29 | $5.08M derived: sum of 3 quarters · filed 2019-03-29 | $8.60M 10-K · filed 2019-03-29 | ||||
| 2017-09-30 | $3.77M 10-Q · filed 2018-11-14 | $4.95M derived: sum of 2 quarters · filed 2018-11-14 | $8.47M 10-Q · filed 2018-11-14 | $10.24M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $1.18M 10-Q · filed 2018-08-14 | $4.70M 10-Q · filed 2018-08-14 | $6.47M derived: sum of 3 quarters · filed 2018-08-14 | $8.01M derived: sum of 4 quarters · filed 2018-08-14 | ||||
| 2017-03-31 | $3.52M 10-Q · filed 2018-05-15 | $5.29M derived: sum of 2 quarters · filed 2018-05-15 | $6.83M derived: sum of 3 quarters · filed 2018-05-15 | $8.43M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $1.77M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $3.31M derived: sum of 2 quarters · filed 2018-03-01 | $4.91M derived: sum of 3 quarters · filed 2018-03-01 | $6.55M 10-K · filed 2018-03-01 | ||||
| 2016-09-30 | $1.54M 10-Q/A · filed 2018-02-28 | $3.13M derived: sum of 2 quarters · filed 2018-02-28 | $4.78M 10-Q/A · filed 2018-02-28 | $11.81M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-06-30 | $1.60M 10-Q/A · filed 2018-02-28 | $3.25M 10-Q/A · filed 2018-02-28 | $10.27M derived: sum of 3 quarters · filed 2018-02-28 | $12.00M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-03-31 | $1.65M 10-Q/A · filed 2018-02-28 | $8.67M derived: sum of 2 quarters · filed 2018-02-28 | $10.40M derived: sum of 3 quarters · filed 2018-02-28 | $11.25M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-12-31 | $7.03M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-02-28 | $8.75M derived: sum of 2 quarters · filed 2018-02-28 | $9.60M derived: sum of 3 quarters · filed 2018-02-28 | $17.04M 10-K/A · filed 2018-02-28 | ||||
| 2015-09-30 | $1.72M 10-Q/A · filed 2018-02-28 | $2.57M derived: sum of 2 quarters · filed 2018-02-28 | $10.01M 10-Q/A · filed 2018-02-28 | $11.53M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-06-30 | $849.00K 10-Q/A · filed 2018-02-28 | $8.29M 10-Q/A · filed 2018-02-28 | $9.81M derived: sum of 3 quarters · filed 2018-02-28 | $13.07M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-03-31 | $7.44M 10-Q/A · filed 2018-02-28 | $8.96M derived: sum of 2 quarters · filed 2018-02-28 | $12.22M derived: sum of 3 quarters · filed 2018-02-28 | $12.39M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2014-12-31 | $1.52M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-02-28 | $4.78M derived: sum of 2 quarters · filed 2018-02-28 | $4.95M derived: sum of 3 quarters · filed 2018-02-28 | $5.15M 10-K/A · filed 2018-02-28 | ||||
| 2014-09-30 | $3.26M 10-Q · filed 2015-11-13 | $3.43M derived: sum of 2 quarters · filed 2015-11-13 | $3.63M 10-Q · filed 2015-11-13 | $3.82M derived: sum of 4 quarters · filed 2015-11-13 | ||||
| 2014-06-30 | $168.00K 10-Q · filed 2015-08-14 | $365.00K 10-Q · filed 2015-08-14 | $559.00K derived: sum of 3 quarters · filed 2015-08-14 | $774.00K derived: sum of 4 quarters · filed 2015-08-14 | ||||
| 2014-03-31 | $197.00K 10-Q · filed 2015-05-14 | $391.00K derived: sum of 2 quarters · filed 2015-05-14 | $606.00K derived: sum of 3 quarters · filed 2015-05-14 | $862.00K derived: sum of 4 quarters · filed 2015-05-14 | ||||
| 2013-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $409.00K derived: sum of 2 quarters · filed 2015-03-31 | $665.00K derived: sum of 3 quarters · filed 2015-03-31 | $1.20M 10-K · filed 2015-03-31 | ||||
| 2013-09-30 | $215.00K 10-Q · filed 2014-12-17 | $471.00K derived: sum of 2 quarters · filed 2015-01-08 | $1.00M 10-Q · filed 2015-01-08 | $1.35M derived: sum of 4 quarters · filed 2015-01-08 | ||||
| 2013-06-30 | $256.00K 10-Q · filed 2015-01-08 | $787.00K 10-Q · filed 2015-01-08 | $1.14M derived: sum of 3 quarters · filed 2015-01-08 | $1.20M derived: sum of 4 quarters · filed 2015-01-08 | ||||
| 2013-03-31 | $531.00K 10-Q · filed 2015-01-08 | $879.00K derived: sum of 2 quarters · filed 2015-01-08 | $944.00K derived: sum of 3 quarters · filed 2015-01-08 | $2.11M derived: sum of 4 quarters · filed 2015-01-08 | ||||
| 2012-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-08 | $413.00K derived: sum of 2 quarters · filed 2015-01-08 | $1.58M derived: sum of 3 quarters · filed 2015-01-08 | $1.65M 10-K · filed 2015-01-08 | ||||
| 2012-09-30 | $65.00K 10-Q · filed 2014-12-17 | $1.23M derived: sum of 2 quarters · filed 2014-12-17 | $1.30M 10-Q · filed 2014-12-17 | $1.40M derived: sum of 4 quarters · filed 2014-12-17 | ||||
| 2012-06-30 | $1.17M 10-Q · filed 2014-12-12 | $1.24M 10-Q · filed 2014-12-12 | $1.33M derived: sum of 3 quarters · filed 2014-12-12 | $1.45M derived: sum of 4 quarters · filed 2014-12-12 | ||||
| 2012-03-31 | $74.00K 10-Q · filed 2014-12-10 | $165.00K derived: sum of 2 quarters · filed 2014-12-10 | $282.00K derived: sum of 3 quarters · filed 2014-12-10 | $462.00K derived: sum of 4 quarters · filed 2014-12-10 | ||||
| 2011-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-18 | $208.00K derived: sum of 2 quarters · filed 2014-11-18 | $388.00K derived: sum of 3 quarters · filed 2014-11-18 | $556.00K 10-K · filed 2014-11-18 | ||||
| 2011-09-30 | $117.00K 10-Q · filed 2012-11-21 | -$117.00K 10-Q · filed 2011-11-21 | $297.00K derived: sum of 2 quarters · filed 2012-11-21 | $465.00K 10-Q · filed 2012-11-21 | -$465.00K 10-Q · filed 2011-11-21 | $1.40M derived: sum of 4 quarters · filed 2012-11-21 | ||
| 2011-06-30 | $180.00K 10-Q/A · filed 2012-09-13 | -$180.00K 10-Q/A · filed 2011-09-12 | $348.00K 10-Q/A · filed 2012-09-13 | -$348.00K 10-Q/A · filed 2011-09-12 | $1.28M derived: sum of 3 quarters · filed 2012-09-13 | $1.26M derived: sum of 4 quarters · filed 2012-09-13 | ||
| 2011-03-31 | $168.00K 10-Q · filed 2012-05-21 | $1.10M derived: sum of 2 quarters · filed 2012-05-21 | $1.08M derived: sum of 3 quarters · filed 2012-05-21 | $1.09M derived: sum of 4 quarters · filed 2012-05-21 | ||||
| 2010-12-31 | $935.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $912.00K derived: sum of 2 quarters · filed 2012-04-16 | $924.00K derived: sum of 3 quarters · filed 2012-04-16 | $513.00K 10-K · filed 2012-04-16 | ||||
| 2010-09-30 | -$23.00K 10-Q · filed 2011-11-21 | -$11.00K derived: sum of 2 quarters · filed 2011-11-21 | -$422.00K 10-Q · filed 2011-11-21 | |||||
| 2010-06-30 | $12.00K 10-Q/A · filed 2011-09-12 | -$384.00K 10-Q/A · filed 2011-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |